Archives
-
Bufuralol Hydrochloride in Organoid Assays
2026-09-22
Bufuralol hydrochloride connects β-receptor pharmacology with human intestinal organoid workflows for studying exposure, transport, and metabolism. This guide outlines a practical 3D-to-2D assay strategy, concentration screening plan, and troubleshooting framework that separates true β-adrenergic effects from vehicle, maturity, and barrier artifacts.
-
MAPK10–KRT16 Signaling in NSCLC Metastasis
2026-09-21
The reference study identifies MAPK10 as a metastasis-suppressing kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-mediated ubiquitination and proteasomal degradation. Its integrated cellular, animal, and clinical analyses position the MAPK10/KRT16/RNF213 axis as a mechanistic framework for studying NSCLC dissemination and as a candidate prognostic pathway.
-
METTL16–SENP3–LTF Axis in HCC Ferroptosis
2026-09-21
Wang et al. identify a METTL16–SENP3–LTF regulatory axis that links m6A-dependent RNA regulation with SUMOylation, iron handling, and ferroptosis resistance in hepatocellular carcinoma. The study combines cell, organoid, xenograft, genetically engineered mouse, biochemical, and human-sample analyses to establish this axis as a mechanistic driver of tumor progression and a potential sensitization target.
-
SkQ1, Mitochondrial Apoptosis, and Muscle Atrophy
2026-09-20
The reference study used a time-resolved ovarian cancer model and chronic mitochondrial antioxidant treatment to test whether mitochondrial hydrogen peroxide, apoptosis, or necroptosis drives skeletal muscle atrophy. SkQ1 normalized late-stage mitochondrial peroxide emission and caspase-9/-3 activity without restoring type IIB fibre size, challenging a simple causal model of mitochondrial oxidative stress–dependent muscle loss.
-
25-Hydroxycholesterol Reprograms TAM Immunity
2026-09-19
Xiao et al. identify CH25H-derived 25-hydroxycholesterol (25HC) as an immunometabolic checkpoint in tumor-associated macrophages. The study links lysosomal 25HC accumulation to GPR155–mTORC1 inhibition, AMPKα activation, STAT6 phosphorylation, and ARG1-dependent immunosuppression, while showing that CH25H targeting can improve anti-tumor responses with or without anti-PD-1 therapy.
-
Tau Ser356, NUAK Inhibition, and Alzheimer’s Pathology
2026-09-18
Taylor et al. characterize tau phosphorylated at serine 356 as a pathology-associated species that increases with Alzheimer’s disease progression and is frequently found in neurofibrillary tangles. Their ex vivo experiments further show that NUAK inhibition with WZ4003 lowers p-tau Ser356 in human brain slices, while producing broader and potentially damaging protein changes in postnatal mouse cultures.
-
Tofacitinib Workflows for RA Macrophage Research
2026-09-18
Tofacitinib (CP-690550) enables researchers to connect JAK/STAT-dependent cytokine signaling blockade with macrophage metabolism, mitochondrial structure, and inflammatory phenotype. This practical workflow combines dose-response testing, phospho-STAT5 analysis, cytokine profiling, and mitochondrial readouts to distinguish pathway inhibition from broader immune-cell stress.
-
Anisomycin Beyond JNK: Reading Apoptosis Assays
2026-09-17
Anisomycin is a JNK agonist that can expose how stress signaling, apoptosis, and assay timing interact. This article connects its cancer-biology applications with a social-memory study to clarify what JNK perturbation can—and cannot—prove in mechanistic experiments.
-
NHE1, Octanal/Olfr2, and Atherosclerosis
2026-09-17
The reference study identifies macrophage NHE1 as a downstream mediator of octanal/Olfr2-driven atherosclerosis, linking calcium signaling to ROS production, NLRP3 inflammasome activation, foam-cell formation, and vascular inflammation. Its combined mouse and macrophage experiments support NHE1 as a mechanistic target, while also highlighting the need for validation beyond the experimental models used.
-
Novobiocin: A Translational Mechanism Playbook
2026-09-16
Novobiocin is more than a legacy antibiotic: its coordinated effects on bacterial DNA gyrase, Hsp90, membrane biology, and pathogen stress create a strategic platform for antibacterial resistance research, antiparasitic discovery, and antiviral model development.
-
5X Protein Loading Buffer (Reducing): Practical SDS-PAGE
2026-09-16
5X Protein Loading Buffer (Reducing), SKU K1164, prepares protein samples for denaturing, reducing SDS-PAGE by combining SDS, a sulfhydryl reducing agent, buffer salts, and bromophenol blue. It is intended for protein molecular weight separation under reducing conditions and should not be used when native structure, biological activity, or non-reducing disulfide patterns must be preserved.
-
Filipin III for Membrane Cholesterol Detection
2026-09-15
Filipin III is a polyene macrolide antibiotic that binds membrane cholesterol and supports cholesterol detection in membranes. Its aggregate formation, sterol-dependent vesicle lysis, and fluorescence changes make it useful for membrane cholesterol visualization, provided that accessibility, controls, and optical behavior are validated in the chosen workflow.
-
Filipin III: Reliable Membrane Cholesterol Data
2026-09-15
Learn how Filipin III (SKU B6034) can complement viability, proliferation, and cytotoxicity assays by mapping membrane cholesterol with an evidence-based workflow. This scenario-driven guide covers compatibility, handling, interpretation, and practical vendor-selection criteria.
-
Cy3 Rabbit Anti-Goat IgG (H+L) Guide
2026-09-14
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat IgG primary antibodies in ICC/IF, frozen or paraffin tissue staining, flow cytometry, and ELISA workflows. It should not be used as a substitute for a goat-specific primary antibody, for non-goat immunoglobulins, or for unvalidated applications without appropriate controls.
-
Alpha-2 Signaling in Itch–Pain Regulation
2026-09-14
This 2025 Brain Research Bulletin study identifies a descending locus coeruleus-to-spinal cord noradrenergic pathway that oppositely regulates itch and pain through spinal alpha-2 adrenergic receptors. By combining behavioral assays, immunofluorescence, electrophysiology, chemogenetic manipulation, and intrathecal pharmacology, the authors distinguish cell-body activity from pathway-specific control.